Sophia Genetics, AstraZeneca Spain to increase ovarian cancer testing in Spain

Sophia Genetics (SOPH) announced it has expanded an existing program in Spain to increase access to local testing for homologous recombination deficiency, or HRD, throughout the country. The expansion of the program, supported by AstraZeneca (AZN) Spain and its network throughout the country, will further Sophia Genetics’ commitment to global health equity by making this vital testing available to thousands more patients in the country.